期刊
CURRENT OSTEOPOROSIS REPORTS
卷 10, 期 3, 页码 217-220出版社
SPRINGER
DOI: 10.1007/s11914-012-0111-6
关键词
Osteoporosis; Screening; Frequency; Interval; Bone density testing
资金
- Amgen
- Eli Lilly
- Merck
- GlaxoSmithKline
Measurement of bone mineral density (BMD) is underutilized, contributing to the underdiagnosis and under-treatment of osteoporosis. Appropriate patient selection for BMD testing leads to more people being treated, fewer fractures, and a decrease in fracture-related health care costs. Although there are well-established indications for BMD testing, it is less clear when a BMD test should be repeated for a patient who does not have osteoporosis and is found to be at low fracture risk with initial testing. BMD testing intervals should be individualized according to the likelihood that the results will influence treatment decisions.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据